PDF Version Merger creates a clinical-stage biopharmaceutical company focused on the discovery and development of select microRNA-targeted therapies Combined company, renamed Miragen Therapeutics, Inc., to commence trading on Nasdaq under the symbol “MGEN” on February 14 Capitalized with approximately $60 million in cash, including $40.7 million equity financing, to advance miRagen’s portfolio BOULDER, Colo., Feb. 13, 2017 (GLOBE NEWSWIRE) - Miragen Therapeutics, Inc. (Nasdaq:MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of microRNA-targeted therapies, today announced the completion of its merger with Signal Genetics, Inc., effective February 13, 2017. Concurrent with the closing of the merger, miRagen received gross proceeds of $40.7 million in new equity investment from a combination of current and new miRagen investors, including Fidelity Management and Research Company, Brace Pharma Capital, Atlas Venture, Boulder Ventures,

Viridian Therapeutics, Inc. (NASDAQ:VRDN) receives average recommendation of "Moderate Buy" from brokerages. August 11, 2026 Key points. * Analyst sentiment is moderately bullish: Fourteen brokerages give Viridian Therapeutics a consensus "Moderate Buy" rating, with 13 buy ratings and one sell rating. The average 12-month price target is $38.93 versus a recent share price of $23.06. * Quarterly results fell slightly short of expectations: Viridian reported a loss of $1.05 per share, missing the $1.03 consensus estimate, while revenue of $0.28 million exceeded expectations. Analysts project a full-year loss of $4.02 per share. * Institutional ownership has increased: Major investors including Perceptive Advisors and Vanguard expanded their positions, while Jennison Associates and Avoro Capital initiated new stakes during the fourth quarter. * Five stocks we like better than Viridian Therapeutics. Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given an average recommendation of "Moderate Buy" by the fourteen brokerages that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and thirteen have issued a buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $38.9286. VRDN has been the subject of a number of research reports. Needham & Company LLC reissued a "buy" rating and issued a $32.00 price target on shares of Viridian Therapeutics in a research note on Monday, June 29th. Evercore set a $26.00 price objective on shares of Viridian Therapeutics in a research report on Friday, May 15th. Royal Bank Of Canada lifted their price objective on shares of Viridian Therapeutics from $35.00 to $36.00 and gave the stock an "outperform" rating in a report on Friday. Wall Street Zen lowered shares of Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 1st. Finally, Weiss Ratings cut Viridian Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Tuesday, June 30th. Viridian Therapeutics stock performance. Shares of VRDN opened at $23.06 on Tuesday. Viridian Therapeutics has a 12-month low of $13.18 and a 12-month high of $34.29. The company has a current ratio of 15.15, a quick ratio of 15.15 and a debt-to-equity ratio of 0.10. The company has a market cap of $2.61 billion, a PE ratio of -6.84 and a beta of 0.91. The stock has a 50-day moving average price of $18.51 and a 200-day moving average price of $21.52. Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.02). The company had revenue of $0.28 million during the quarter, compared to the consensus estimate of $0.06 million. Viridian Therapeutics had a negative return on equity of 76.65% and a negative net margin of 505.86%. As a group, equities analysts forecast that Viridian Therapeutics will post -4.02 earnings per share for the current fiscal year. Hedge funds weigh in on Viridian Therapeutics. A number of hedge funds and other institutional investors have recently modified their holdings of the company. Perceptive Advisors LLC lifted its holdings in shares of Viridian Therapeutics by 108.1% in the 4th quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company's stock worth $94,689,000 after acquiring an additional 1,580,303 shares during the last quarter. Jennison Associates LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at $35,915,000. Avoro Capital Advisors LLC bought a new position in shares of Viridian Therapeutics during the 4th quarter valued at $46,680,000. Vanguard Group Inc. raised its position in Viridian Therapeutics by 29.6% in the 4th quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company's stock worth $174,650,000 after purchasing an additional 1,280,161 shares during the period. Finally, Privium Fund Management B.V. purchased a new position in Viridian Therapeutics in the 4th quarter worth $5,400,000. Viridian Therapeutics company profile. Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders. Discover more MarketBeat Research Tools AI Stocks Report Market Cap Calculator In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Viridian Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list. While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Wedbush raised its price target on Viridian Therapeutics to $43 from $32 following FDA approval of Lumvoa, a thyroid eye disease treatment. The firm maintained its Outperform rating, citing the drug's competitive advantages. Lumvoa will be priced at $450,000 per treatment course, matching competitor Tepezza. Its label covers both active and chronic thyroid eye disease patients, providing a strong market position. Truist also increased its target to $38 from $35, highlighting Lumvoa's more convenient dosing schedule whilst maintaining pricing parity with the market leader. The Massachusetts-based biopharmaceutical company expects meaningful revenue by 2027 and plans a subcutaneous formulation with a biologics licence application anticipated in early 2027.